Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alsace trial: afatinib for solid tumors with NRG1 fusion
jRCT2041220036Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of afatinib in Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: Response rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2041220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220036.